Evidence map›Paper›PMID 36817850›Full record

ArticleCase reports in dermatology

Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report.

Angelo Ruggiero, Wanda Lauro, Chiara Miano, Alessia Villani, Gabriella Fabbrocini, Claudio Marasca

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Hidradenitis Suppurativa Cancer Risk: A Review of the Literature.Clinical, cosmetic and investigational dermatology · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Angelo RuggieroSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Wanda LauroSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Chiara MianoSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Alessia VillaniSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Gabriella FabbrociniSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Claudio MarascaSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
University of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hidradenitis suppurativa (HS) is an inflammatory skin disease showing a chronic-remitting course. It has been rarely reported that long-term inflammation in HS could lead to serious complications like cutaneous squamous cell carcinoma. Cemiplimab is a fully human antibody immunotherapy that inhibits programmed cell death protein-1, approved for the treatment of locally advanced squamous cell carcinoma, or metastatic squamous cell carcinoma, in patients not eligible for curative surgery or radiotherapy. Herein, we report the case of a 56-year-old patient developing an invasive SCC on longstanding and unresponsive HS lesions successfully treated with cemiplimab.

Indexed as

CemiplimabHidradenitis suppurativaSquamous cell carcinoma

Identifiers

PMID36817850
PMCPMC9929653
OpenAlexW4320716988

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.